This is a list of all the questions and their associated study carrel identifiers. One can learn a lot of the "aboutness" of a text simply by reading the questions.
| identifier | question |
|---|---|
| cord-277146-4a4vz36h | Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis, Haemostasis? |
| cord-274542-fpzk5k79 | should we be limiting their use in the clinical setting? |
| cord-306997-84pjfawk | The single nucleotide polymorphism Ser128Arg in the E- selectin gene is associated with enhanced coagulation during human endotoxemia Prevention and treatment of acute renal failure in sepsis Risk factor for venous thromboembolism in hospitalized patient with acute medical illness: analysis of the MEDENOX Study Fibrinolysis and inflammation in venous thrombus resolution Pulmonary thrombosis in 2019-nCoV pneumonia? |
| cord-257939-tgpsd3r7 | Two complications of COVID-19 pneumonia? |
| cord-282636-u0ea02fc | The Emerging Role of Neutrophil Extracellular Traps in Respiratory Disease Neutrophil Extracellular Traps in Pulmonary Diseases: Too Much of a Good Thing? |
| cord-342603-k0f33p3l | COVID-19 pneumonia: a random association? |
| cord-320822-etibcspx | Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study Influence of Fibrinolysin on Shock Disseminated Intravascular Coagulation with Special Reference to Shock and Its Treatment Studies on the role of intravascular coagulation in irreversible hemorrhagic shock Mechanism of action of fibrinolysin in the prevention of irreversible hemorrhagic shock Pulmonary vascular obstruction in severe ARDS: angiographic alterations after i.v. fibrinolytic therapy Treatment of severe acute respiratory distress syndrome: a final report on a phase I study Is There a Role for Tissue Plasminogen Activator( tPA) as a Novel Treatment for Refractory COVID-19 Associated Acute Respiratory Distress Syndrome( ARDS)? |
| cord-320822-etibcspx | Can Thromboelastography Predict Venous Thromboembolic Events in Patients with Severe Extremity Trauma? |
| cord-301493-32l52q3s | A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score Predictive and associative models to identify hospitalized medical patients at risk for VTE Extended vs. standard- duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta- analysis Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis Incidence of venous thromboembolism in hospitalized patients with COVID-19 Clinical characteristics of Covid-19 in New York City Pulmonary embolism or pulmonary thrombosis in COVID-19? |
| cord-301493-32l52q3s | Is the recommendation to use high- dose heparin for thromboprophylaxis justified? |
| cord-291483-ni6toh8c | A H1N1 acute respiratory distress syndrome patients H1N1-induced venous thromboembolic events? |
| cord-291483-ni6toh8c | Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D- Dimer Levels Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Pulmonary embolism or pulmonary thrombosis in COVID-19? |
| cord-291483-ni6toh8c | Is the recommendation to use high- dose heparin for thromboprophylaxis justified? |
| cord-296607-h2zwlyz7 | Reperfusion of STEMI in the COVID-19 era-business as usual? |
| cord-296607-h2zwlyz7 | phase 3b study on behalf of the COVID-19& AMI committee of Peking Union Medical College Hospital, recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing( almost) everything? |
| cord-324245-cfiekxr4 | Can the US examination for lower extremity deep venous thrombosis be abbreviated? |
| cord-324245-cfiekxr4 | This high prevalence of asymptomatic DVT patients, even with a standard thromboprophylaxis, poses us a crucial question: how and when to suspect VTE in this particular medical condition? |
| cord-297001-4g3wb8qi | Covid-19 Will complement inhibition be the new target in treating CO- VID-19 related systemic thrombosis? |
| cord-297001-4g3wb8qi | Far? date: 2020- 05- 12 journal: |
| cord-297001-4g3wb8qi | a descriptive study Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Clinical characteristics of coronavirus disease 2019 in China Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology( ESC) Acute management of pulmonary embolism Thrombosis: a major contributor to global disease burden Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19 D- dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study Acute pulmonary embolism and COVID-19 pneumonia: a random association? |
| cord-339695-3ij5pjjy | A report of thromboelastography findings and other parameters of hemostasis COVID-19 and thrombotic complications: Pulmonary thrombosis rather than embolism? |
| cord-339695-3ij5pjjy | Is the Recommendation to Use High- Dose Heparin for Thromboprophylaxis Justified? |
| cord-339695-3ij5pjjy | Non- Overt Coagulopathy in Non- ICU Patients with Mild to Moderate COVID-19 Pneumonia Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? |
| cord-009997-oecpqf1j | Questions addressed their current feeding route and perception, for example,"What aspect(s) of tube feedings are beneficial to you?" |
| cord-009997-oecpqf1j | The question remains: which mechanisms influence platelet immune function and are they developmentally regulated? |
| cord-009997-oecpqf1j | and"What aspect(s) of tube feeding worry or scare you? |
| cord-336000-v88bq4bx | Autopsy findings in eight patients with fatal H1N1 influenza H1N1-Induced Venous Thromboembolic Events? |
| cord-336000-v88bq4bx | Due to Occurrence of Pulmonary Vascular Thrombosis? |
| cord-336000-v88bq4bx | Results of a Single- Institution Case Series Acute Pulmonary Embolism and COVID-19 Pneumonia: A Random Association? |
| cord-336000-v88bq4bx | What Is the Evidence? |
| cord-326272-ya3r0h1t | A potential link between the renin- angiotensinaldosterone system and thrombosis Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Deep vein thrombosis in hospitalized patients with coronavirus disease 2019( COVID-19) in Wuhan, China: prevalence, risk factors, and outcome Extremely high incidence of lower extremity deep vein thrombosis in 48 patients with severe COVID-19 in Wuhan High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients Incidence of venous thromboembolism in critically ill coronavirus disease 2019 patients receiving prophylactic anticoagulation Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Thromboembolic events and apparent heparin resistance in patients infected with SARS- CoV-2 Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease 2019 Prevalence of venous thromboembolism in critically ill patients with COVID-19 Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D- dimer levels Incidence of deep vein thrombosis among non- ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis Venous thromboembolism in SARS- CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it? |
| cord-326272-ya3r0h1t | Is the recommendation to use high- dose heparin for thromboprophylaxis justified? |
| cord-326272-ya3r0h1t | LAC) testing in patients with inflammatory status: does C- reactive protein interfere with LAC test results? |
| cord-326272-ya3r0h1t | The old but new: can unfractionated heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS- CoV2 by inhibition of host cell proteases? |
| cord-326272-ya3r0h1t | The source of elevated plasma D- dimer levels in COVID-19 infection D- dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial Pulmonary thrombosis in 2019-nCoV pneumonia? |
| cord-326272-ya3r0h1t | a multicenter prospective cohort study Pulmonary embolism or pulmonary thrombosis in COVID-19? |
| cord-327370-zo0n8wf6 | Acute pulmonary embolism associated with COVID-19 pneumonia detected with pulmonary CT angiography Scientific and standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the Respiratory failure as an indication for thrombolysis in pulmonary embolism? |
| cord-327370-zo0n8wf6 | COVID-19 infection: origin, transmission, and characteristics of human coronaviruses Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? |
| cord-327370-zo0n8wf6 | COVID-19 pneumonia: a random association? |
| cord-327370-zo0n8wf6 | Is interleukin-6( IL-6) the'culprit lesion'of ARDS onset? |
| cord-327370-zo0n8wf6 | Thrombolysis in pulmonary embolism: are we under- using it? |
| cord-327370-zo0n8wf6 | What is there besides Tocilizumab? |
| cord-327370-zo0n8wf6 | do heparins have direct anti- inflammatory effects? |
| cord-006870-f5w6fw6q | : Are you aware that Medicare can reject critical care charges( 99291 and 99292) can be rejected unless you are listed as a CMS'critical care provider'or as a neurocritical care provider? |
| cord-006870-f5w6fw6q | A management QEEG ADR in Poor Grade SAH: Is it Really Useful? |
| cord-006870-f5w6fw6q | Lumbar puncture in the presence of mass effect? |
| cord-006870-f5w6fw6q | Neurocritical care taxonomy code 2084A2900X? |
| cord-006870-f5w6fw6q | Q3: Are you aware why the NCC taxonomy code was created? |
| cord-006870-f5w6fw6q | Q6: Are you aware of rejection of critical care charges happening at your own institution due to this misclassification? |
| cord-006870-f5w6fw6q | Question( Q1) and( Answers, A1): Are you a neurology or neurosurgery back grounded intensivist who does neurocritical care at your hospital? |
| cord-006870-f5w6fw6q | What is your primary department for revenue collection? |
| cord-335020-at43c8q7 | COVID-19 pneumonia: a random association? |
| cord-335020-at43c8q7 | Frequently Asked Questions More than an anticoagulant: Do heparins have direct anti- inflammatory effects? |
| cord-335020-at43c8q7 | Is there a need for a dedicated scoring system to estimate the risk of VTE among patients with COVID-19? |
| cord-335020-at43c8q7 | Should patients treated at home receive pharmacological thromboprophylaxis? |
| cord-335020-at43c8q7 | Should we screen COVID-19 patients for DVT at the moment of hospital admission, or during hospitalization? |
| cord-335020-at43c8q7 | Some are the following: What is the prevalence of VTE among patients hospitalized for COVID-19 outside of the ICU? |
| cord-335020-at43c8q7 | What is the optimal dose of anticoagulation to prevent VTE in COVID-19 patients? |
| cord-335020-at43c8q7 | When should we consider performing CTPA to rule out PE in patients with COVID-19 pneumonia? |
| cord-324265-j3v3i8vm | COVID-19 and VTE/ Anticoagulation: frequently asked questions Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST guideline and expert panel report Pulmonary embolism or pulmonary thrombosis in COVID-19? |
| cord-324265-j3v3i8vm | How do we frame the COVID-19 associated coagulopathy? |
| cord-324265-j3v3i8vm | How do we frame the COVID-19-associated coagulopathy, that is, DIC, SIC, CAC or PIC? |
| cord-324265-j3v3i8vm | How do we gather these puzzling data on a unified clinicopathological picture, helpful to improve the management of CAC? |
| cord-324265-j3v3i8vm | How do we tackle COVID-19 coagulopathy? |
| cord-324265-j3v3i8vm | Is the recommendation to use high- dose heparin for thromboprophylaxis justified? |
| cord-324265-j3v3i8vm | The role of heparin in sepsis: much more than just an anticoagulant The versatile heparin in COVID-19 Both UFH and NAH alleviate shedding of endothelial glycocalyx and coagulopathy in LPS- induced sepsis Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells Pulmonary thrombosis in 2019-nCoV pneumonia? |
| cord-324265-j3v3i8vm | This review is particularly focused on four clinical questions: What is the incidence of VTE in COVID-19 patients? |
| cord-324265-j3v3i8vm | Which role, if any, do antiphospolipid antibodies have? |
| cord-324265-j3v3i8vm | an update on experimental models and clinical data Tissue factor: an essential mediator of hemostasis and trigger of thrombosis Clinical and immunologic features in severe and moderate Coronavirus Disease COVID-19 gone bad: a new character in the spectrum of the hyperferritinemic syndrome? |